Skip to navigation Skip to content



About this Medication
  • Brand Name: Gilenya® (U.S.) (je-LEN-yah)
  • Chemical Name: fingolimod (fin-GOL-i-mod)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: Yes

This is an oral medication in capsule form.


Gilenya® is a new class of medication called a sphingosine 1-phosphate receptor modulator, which is thought to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Gilenya was approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

Click here to read the Gilenya Prescribing Information for healthcare professionals.

Click here to read the Gilenya Medication Guide for patients.

Financial Assistance Program

For co-pay assistance, contact 1-855-443-1759.


Gilenya®: What is it and How Does it Work?

This video features part one of a two-part interview with Aaron Miller, MD, who discusses Gilenya® and was created in 2010.  In April of 2012 the FDA revised the prescribing information for Gilenya.  To learn more about Gilenya® and other disease modifying treatment options, download the Consensus on Disease-Modifying Therapies.

Watch Now


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.